Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - TRIM8 FGFR2 E565A FGFR2 L617V FGFR2 K659M||cholangiocarcinoma||predicted - resistant||Pemigatinib||Case Reports/Case Series||Actionable||In a Phase II trial (FIGHT-202), a cholangiocarcinoma patient harboring FGFR2-TRIM8 experienced disease progression after 9.1 months of treatment with Pemazyre (pemigatinib), and was found to have acquired FGFR2 E565A, FGFR2 L617V, and FGFR2 K659M (PMID: 33218975; NCT02924376).||33218975|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|